Investigators assessed fixed-duration venetoclax plus acalabrutinib with or without obinutuzumab vs chemoimmunotherapy.
Matthew Chui, PharmD, BCOP
Advertisement
Articles by Matthew Chui, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Anitocabtagene Autoleucel Demonstrates Deep, Durable Responses and Improved MRD-Negativity in RRMM
2
Inclisiran, PCSK9s Elicits Sustained LDL-C Reductions in Familial Hypercholestrolemia
3
Delayed Statin Initiation Following Detection of High LDL-C Raises Risk of Heart Attack
4
Biolinq Shine Receives FDA De Novo Classification as First Multi-Analyte Wearable for Type 2 Diabetes
5
